Palm oil

Controlled feeding trials and meta-analyses generally find palm oil raises LDL cholesterol more than oils richer in unsaturated fat, such as olive, canola, or soybean oil. That does not automatically prove more heart attacks in every diet pattern, but LDL is a well-established cardiovascular risk marker, so this is the strongest evidence-based reason for caution. The size of the effect depends on what palm oil replaces: replacing butter or trans fat is a different question from replacing extra-virgin olive oil.

This is the part many headlines overstate. Direct human outcome evidence specific to palm oil is much thinner than the blood-lipid literature, and it is hard to separate palm oil itself from the ultra-processed foods that often contain it. The overall picture is mixed: palm oil looks less favourable than many unsaturated oils on LDL, but the evidence tying it on its own to higher heart attack or mortality risk is not clean or consistent enough to make the ingredient a standalone villain.

Palm oil became popular in part because it can provide structure without creating industrial trans fats. That matters: replacing partially hydrogenated oils with palm oil was generally an improvement on older trans-fat-heavy formulations. But that does not make palm oil the optimal fat from a cardiometabolic perspective. If the comparison is trans fat, palm oil can look relatively better; if the comparison is olive, canola, or other unsaturated oils, palm oil usually looks less favourable.

Online discussions often jump from 'saturated fat' to 'inflammation' as if the case were settled. It is not. Human evidence here is limited and less consistent than the LDL story. Some mechanistic and postprandial studies raise plausible concerns, but short-term trials do not show a clear, uniform signal that palm-oil intake uniquely worsens insulin resistance or systemic inflammation compared with every alternative. If there is risk, it is more likely mediated through broader dietary pattern and fat substitution than a special inflammatory property of palm oil itself.

This depends heavily on the form. Red palm oil contains carotenoids and tocotrienols, and trials in deficiency contexts suggest it can improve vitamin A status. But that does not describe the highly refined palm oil used in most biscuits, spreads, and fried snacks, where much of the colour and some of the phytonutrient content are reduced. So the 'palm oil is healthy because of antioxidants' claim is too broad: it is more defensible for red palm oil than for standard refined palm oil in ultra-processed food.

Palm olein is relatively stable for frying compared with some more polyunsaturated oils, which is one reason industry likes it. But 'more stable' does not mean 'immune to damage.' Repeated high-heat use still increases oxidation and degradation products, especially in commercial or repeated-fry settings. The practical takeaway is that reuse practices matter more than simplistic claims that palm oil is either uniquely safe or uniquely dangerous for heat. One-off home use is not the same exposure as repeatedly reheated fryer oil.

For many people, the strongest objection to palm oil is environmental, not nutritional. The evidence base here is mostly land-use, sustainability, and public-health literature rather than feeding trials: expansion of palm plantations has been linked to deforestation, biodiversity loss, and downstream community harms in some producing regions. That does not prove the oil is chemically toxic to the eater, but it does mean 'is palm oil bad?' can be a legitimate yes from an environmental ethics perspective even when the human-health case is more nuanced.

This is the wrong frame. No good human evidence suggests palm oil alone determines health outcomes independent of the diet around it. The bigger predictors remain total dietary pattern, energy balance, fibre intake, smoking, exercise, and what fats palm oil is replacing. A palm-oil-free biscuit can still be nutritionally poor, while a small amount of palm oil in an otherwise minimally processed, high-fibre diet is unlikely to be the main driver of risk. Context beats ingredient moralising.